首页 | 本学科首页   官方微博 | 高级检索  
     


T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized,Double-Blind Clinical Trial
Authors:Dimitrios Karussis  Hagai Shor  Julia Yachnin  Naama Lanxner  Merav Amiel  Keren Baruch  Yael Keren-Zur  Ofra Haviv  Massimo Filippi  Panayiota Petrou  Shalom Hajag  Urania Vourka-Karussis  Adi Vaknin-Dembinsky  Salim Khoury  Oded Abramsky  Henri Atlan  Irun R. Cohen  Rivka Abulafia-Lapid
Affiliation:1. Department of Neurology, MS Center and the Agnes-Ginges Center for Neurogenetics, Hadassah-Hebrew University Hospital, Jerusalem, Israel.; 2. Department of Biophysics and Nuclear Medicine, Human Biology Research Center, Hadassah-Hebrew University Hospital, Jerusalem, Israel.; 3. San Raffaelle Hospital, MS Center, Milan, Italy.; 4. Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel.; Escola Paulista de Medicina - UNIFESP, Brazil,
Abstract:

Background

T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled.

Aim

To evaluate the safety and efficacy of TCV in progressive MS, in a double-blind, controlled clinical trial.

Methodology

Twenty-six patients with relapsing-progressive MS were enrolled in the study (mean age: 39±9.8 years; mean EDSS: 4.4±1.7). T-cell lines reactive to 9 different peptides of the myelin antigens, MBP, MOG and PLP were raised from the patients'' peripheral blood. The patients were randomized into two groups: 19 were treated with TCV (four subcutaneous injections of 10–30×106 T-cells, attenuated by irradiation, on days 1, 30, 90 and 180) and 7 patients were treated with sham injections. Twenty-four patients (17 in the TCV group and 7 in the placebo) were eligible for per-protocol analysis.

Results

At one year following the inclusion, an increase in the EDSS (+0.50) and an increase in 10-meter walking time (+0.18 sec), were observed in the placebo group; in the TCV group there was a decrease in the EDSS (−0.44; p<0.01) and in the 10-meter walking time (0.84 sec; p<0.005). Sixteen of the 17 patients (94.1%) in the TCV group remained relapse-free during the year of the study, as compared to 42.9% in the placebo group (p = 0.01 and p = 0.03 with adjustment). The proportion of patients with any relapse during the year of the study in the TCV-group, was reduced by 89.6%., as compared to the placebo-treated group. MRI parameters did not change significantly.

Conclusions

This is the first controlled, double-blind trial with TCV in progressive MS. The results demonstrate the feasibility and safety of the procedure, and provide significant indications of clinical efficacy. Further studies with larger groups of subjects are warranted.

Trial Registration

ClinicalTrials.gov NCT01448252
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号